ArticleFrontiers in aging neuroscience2026
Longitudinal associations of rest-activity rhythms with executive function, plasma biomarkers, and clinical outcomes in older adults.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: Daily patterns of activity, rest, and sleep, referred to as rest-activity rhythms (RARs), can be characterized by their day-to-day regularity, within-day fragmentation, and contrast between active and rest periods across the 24-h cycle. Disruptions (e.g., irregular schedules, fragmented activity, or reduced day-night contrast) have been associated with cognitive decline among older adults. Few studies have used repeated actigraphy to distinguish person-level average RARs from visit-specific deviations. Methods: The sample included 169 older adults without MCI or dementia at the first actigraphy visit, based on consensus clinical and neuropsychological review. Seven-day wrist actigraphy required at least three 24-h intervals with <5% missing data each; 122 participants had repeated assessments (362 observations total). RARs were characterized using three non-parametric features: (1) day-night contrast [relative amplitude (RA)], (2) day-to-day regularity [interdaily stability (IS)], and (3) within-day fragmentation [intradaily variability (IV)]. Each metric was decomposed into a person-level average and a visit-specific deviation from that average. Linear mixed-effects models examined associations with executive function and BMI-adjusted plasma markers of Alzheimer's disease-related pathophysiology [pTau181/(Aβ42/Aβ40)], neuroaxonal injury (NfL), and astroglial activation (GFAP); exploratory Cox models evaluated incident MCI; and amyloid PET interaction models were conducted in participants with PET data ( Results: Higher average RA and IS and lower average IV were associated with higher executive function. At the visit level, higher-than-average RA and lower-than-average IV relative to each participant's own average were associated with higher executive function at corresponding assessments. Higher average RA was associated with lower risk of incident MCI. RAR metrics were not significantly associated with GFAP, NfL, or pTau181/(Aβ42/Aβ40) in the plasma biomarker models. Amyloid PET status moderated within-person RAR associations with executive function: higher-than-usual RA and IS and lower-than-usual IV were more strongly associated with better executive function among amyloid PET-positive participants. For the plasma biomarkers, the between-person IS × amyloid PET interaction remained significant after correction only for pTau181/(Aβ42/Aβ40). Discussion: These findings highlight the value of repeated actigraphy for distinguishing average RAR levels from assessment-level departures from each participant's own average RAR profile and suggest that visit-specific RAR variation may be particularly relevant to executive function among amyloid PET-positive older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.